Full article with supplemental data:<p><a href="https://www.biorxiv.org/content/10.1101/2021.12.28.474326v1.full.pdf" rel="nofollow">https://www.biorxiv.org/content/10.1101/2021.12.28.474326v1....</a><p>> "The intranasal dose of TriSb92 that should be administered to susceptible persons prior to events involving a risk for SARS-CoV-2 exposure remains to be established but is likely to be substantially lower than extrapolation of our current data on mice that were challenged by inoculation of the rather massive amount of 2x105 PFU of SARS-CoV-2 into their respiratory tract."<p>Side effects might be an issue but that should show up in well-designed clinical trials. It sounds like something that people working in infectious clinical settings might want to use, maybe immunocompromised people who have to go out in public, but otherwise, for general use seems iffy in terms of efficacy.